Journal of geriatric oncology最新文献

{"title":"Association of age and performance status with adverse events in older adults with diffuse large B-cell lymphoma receiving frontline R-CHOP therapy: Alliance 151930, a secondary analysis of the phase III trial CALGB 50303","authors":"Vicki A. Morrison ,&nbsp;Jennifer Le-Rademacher ,&nbsp;Olivia Bobek ,&nbsp;Daniel Satele ,&nbsp;John P. Leonard ,&nbsp;Aminah Jatoi","doi":"10.1016/j.jgo.2025.102185","DOIUrl":"10.1016/j.jgo.2025.102185","url":null,"abstract":"<div><h3>Introduction</h3><div>Rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) therapy is the standard of care for patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). However, detailed delineation of toxicity data is limited and has not been examined by age. We sought to examine adverse event data in patients receiving R-CHOP from the Cancer and Leukemia Group B (CALGB) 50303 trial to determine if there were differences in grade 3+ toxicities by age cohort or ECOG performance status (PS), and if outcome was impacted by age cohort or toxicity occurrence.</div></div><div><h3>Materials and Methods</h3><div>CALGB 50303 was an intergroup phase III study for previously untreated patients with DLBCL that included R-CHOP as one of the trial arms. In the subset of 235 evaluable, seemingly fit patients receiving R-CHOP on this trial, data regarding the occurrence of grade 3+ hematologic and non-hematologic toxicities by treatment arm, as well as completion of protocol therapy, overall response rate (ORR), and survival outcome parameters were collected and analyzed for Alliance A151930.</div></div><div><h3>Results</h3><div>Data were available for further analysis from 235 of 243 patients evaluable for safety, i.e., those who received R-CHOP therapy on this trial, with 165 being &lt;65 years of age, and 70 ≥ 65 years of age. There was an increased rate of grade 3+ non-hematologic (but not hematologic) toxicities in the older age cohorts, after controlling for disease stage and performance status (<em>p</em> &lt; 0.001). One-year and three-year overall survival (OS) were inferior in patients ≥65 years of age, compared to those &lt;65 years of age; there was no difference in one-year or in three-year progression-free survival (PFS) between the age cohorts.</div></div><div><h3>Discussion</h3><div>Standard frontline therapy with R-CHOP can be effectively administered to an older age cohort. We found more grade 3+ non-hematologic, but not hematologic, toxicities in older patients. These data can be used in clinical trial and real-world settings to identify at-risk DLBCL subgroups for which pro-active measures can be utilized to ensure completion of therapy and optimization of clinical outcomes.</div><div><span><span>Clinicaltrials.gov</span><svg><path></path></svg></span> Identifier: <span><span>NCT00118209</span><svg><path></path></svg></span> (CALGB 50303).</div></div>","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"16 2","pages":"Article 102185"},"PeriodicalIF":3.0,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142983786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relevance of diabetes mellitus as a confounding variable in chemotherapy outcomes","authors":"Amir Reza Akbari ,&nbsp;Benyamin Alam","doi":"10.1016/j.jgo.2025.102188","DOIUrl":"10.1016/j.jgo.2025.102188","url":null,"abstract":"","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"16 2","pages":"Article 102188"},"PeriodicalIF":3.0,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142983122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Increasing the evidence for comprehensive geriatric assessment – Outlook on another work in progress","authors":"Miriam Hüttmeyer ,&nbsp;Kathrin Tatschner ,&nbsp;Elisabeth Jentschke ,&nbsp;Carmen Roch ,&nbsp;Barbara Deschler-Baier","doi":"10.1016/j.jgo.2024.102078","DOIUrl":"10.1016/j.jgo.2024.102078","url":null,"abstract":"","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"16 2","pages":"Article 102078"},"PeriodicalIF":3.0,"publicationDate":"2025-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142978820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the status of online social support for older adults with cancer: A scoping review.","authors":"Fei Liu, Sophie Pilleron, India Pinker","doi":"10.1016/j.jgo.2024.102182","DOIUrl":"https://doi.org/10.1016/j.jgo.2024.102182","url":null,"abstract":"<p><strong>Introduction: </strong>The number of new cancer cases among older adults is rising, yet their social support needs remain unmet due to diminishing social networks with age. Since the COVID-19 pandemic, online technologies have provided increased opportunities for social support for this demographic via digital platforms such as online peer support groups, online communities, and chat rooms. This scoping review explores the current state of the use of online social support for older adults with cancer.</p><p><strong>Materials and methods: </strong>This scoping review was based on the Arksey and O'Malley methodological framework with the extension proposed by Levac and colleagues. The protocol was registered on Open Science Framework (OSF). PubMed, Elsevier Embase (including Medline), and EBSCO CINAHL Complete were searched to identify eligible studies. The review findings were presented in a narrative synthesis.</p><p><strong>Results: </strong>Out of 6542 references, we included three studies. Two studies investigated older patients' preferences for different types of peer support through surveys and questionnaires, and the third examined the feasibility of an online platform for older women with breast cancer. Barriers identified include a lower interest and familiarity, sense of involvement, and emotional impact of a new diagnosis. However, factors such as socio-demographic characteristics and positive motivation for using online peer support act as facilitators.</p><p><strong>Discussion: </strong>This scoping review is the first to examine the literature on online social support specifically for older adults with cancer, revealing a paucity of research. Further research is required to understand the potential need and interest in online social support for this population, especially as technology becomes more integrated into daily life post-COVID.</p>","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":" ","pages":"102182"},"PeriodicalIF":3.0,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142965563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Three lessons from \"The Fox and the Grapes\" to inform precision oncology in the older adult.","authors":"Gabriel Aleixo, Teja Voruganti, Ramy Sedhom","doi":"10.1016/j.jgo.2025.102186","DOIUrl":"https://doi.org/10.1016/j.jgo.2025.102186","url":null,"abstract":"","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":" ","pages":"102186"},"PeriodicalIF":3.0,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142965565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of enfortumab vedotin in older patients with metastatic urothelial carcinoma: A multicenter retrospective study","authors":"Tetsuya Shindo ,&nbsp;Kohei Hashimoto ,&nbsp;Toshiki Kenuka ,&nbsp;Shintaro Miyamoto ,&nbsp;Yoshiki Hiyama ,&nbsp;Fumimasa Fukuta ,&nbsp;Yasuharu Kunishima ,&nbsp;Manabu Okada ,&nbsp;Masanori Matsukawa ,&nbsp;Ryuichi Kato ,&nbsp;Masaya Senda ,&nbsp;Atsushi Wanifuchi ,&nbsp;Shunsuke Sato ,&nbsp;Ko Kobayashi ,&nbsp;Toshiaki Tanaka ,&nbsp;Naoya Masumori ,&nbsp;on behalf of the Sapporo Medical University Urologic Oncology Consortium","doi":"10.1016/j.jgo.2024.102183","DOIUrl":"10.1016/j.jgo.2024.102183","url":null,"abstract":"<div><h3>Introduction</h3><div>We aimed to evaluate the efficacy and safety of enfortumab vedotin therapy for a cohort of older Japanese patients with metastatic urothelial carcinoma compared to younger patients.</div></div><div><h3>Materials and Methods</h3><div>We retrospectively evaluated patients with metastatic urothelial carcinoma treated with enfortumab vedotin and recruited between April 2019 and February 2023. Older patients were defined as being ≥75 years old. Efficacy was evaluated by comparing overall survival, progression-free survival, and objective response rates between groups. Adverse events and relative dose intensity were also compared. Moreover, the prognostic factor for overall survival in the entire cohort was evaluated using multivariate analysis.</div></div><div><h3>Results</h3><div>Of the 57 patients treated with enfortumab vedotin, 37 were younger and 20 were older, (median ages of 67.6 and 79.2, respectively). Median overall survival in older and younger patients was 407 and 365 days, respectively (<em>P</em> = 0.48). The objective response rate was 60.0 % and 54 % (<em>P</em> = 0.68) and median progression-free survival 228 and 223 days in older and younger patients, respectively (<em>P</em> = 0.76). Adverse events were equivalent between groups except for liver dysfunction, which frequently occurred in younger patients. The dose intensity for the older and younger patients did not differ (65.7 % vs. 63.5 %, <em>P</em> = 0.37, respectively). In multivariate analysis, neutrophil-to-lymphocyte ratio of 3 or more was the only risk factor for worse overall survival in the entire cohort (<em>P</em> = 0.04).</div></div><div><h3>Discussion</h3><div>Our data demonstrated that enfortumab vedotin therapy can benefit older patients with metastatic urothelial carcinoma equivalent to younger patients without compromising safety profiles.</div></div>","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"16 2","pages":"Article 102183"},"PeriodicalIF":3.0,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142965557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From healthy aging to complex needs in older adults: Onco-geriatric insights from the EuGMS 2024 conference, a report from Young SIOG.","authors":"Filippo M Verri, Nicolás M González-Senac, Chloé Herledan, Frederiek van den Bos, Nina R Neuendorff","doi":"10.1016/j.jgo.2024.102156","DOIUrl":"https://doi.org/10.1016/j.jgo.2024.102156","url":null,"abstract":"","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":" ","pages":"102156"},"PeriodicalIF":3.0,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142950048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adjuvant taxane-based chemotherapy treatment in older patients with early breast cancer: A pooled analysis of five phase III trials from the Hellenic Oncology Research Group","authors":"Oraianthi Fiste,&nbsp;Lambros Vamvakas,&nbsp;Panagiotis Katsaounis,&nbsp;Nikolaos Vardakis,&nbsp;Sofia Kallianteri,&nbsp;Vassilis Georgoulias,&nbsp;Athanasios Karampeazis","doi":"10.1016/j.jgo.2024.102184","DOIUrl":"10.1016/j.jgo.2024.102184","url":null,"abstract":"<div><h3>Introduction</h3><div>The use of taxanes in the adjuvant setting of early breast cancer (BC) confers survival benefits, however, their role in older patients merits further study. This retrospective pooled analysis of randomized controlled trials conducted by the Hellenic Oncology Research Group (HORG) aims to assess the efficacy and safety of taxane-based adjuvant chemotherapy in older women with BC.</div></div><div><h3>Materials and Methods</h3><div>Five phase III trials containing a taxane, conducted by HORG between 1995 and 2013, were included in a patient-data pooled analysis. The primary endpoint was disease-free survival (DFS) at three years, whereas secondary outcomes included overall survival (OS) at five years and toxicity.</div></div><div><h3>Results</h3><div>A total of 3,026 randomized patients, of whom 701 (23 %) were ≥ 65 years old (median age 69 years; range 65–80), were included in the analysis. No statistically significant heterogeneity in survival was observed between older and younger patients. Within the cohort of older patients, taxane-based regimens were superior to 5-fluorouracil, epirubicin, and cyclophosphamide (FE₇₅C) regimen in terms of three-year DFS (92.02 % vs 77.17 %; <em>p</em> &lt; 0.001) and five-year OS (94.38 % vs 72.64 %; <em>p</em> &lt; 0.001), respectively. A higher number of older patients discontinued treatment compared to younger patients (5.7 % vs 2.9 %; <em>p</em> &lt; 0.001), mainly due to toxicity (3.4 % vs 1.8 %; <em>p</em> = 0.01). The incidence of grade 3–4 neutropenia (35.4 % vs 29.8 %; <em>p</em> = 0.006) and thrombocytopenia (0.8 % vs 0.3 %; <em>p</em> = 0.049) was higher for patients aged ≥65 years compared to those aged &lt;65 years; however, there was no difference in terms of febrile neutropenia and non-hematologic toxicity.</div></div><div><h3>Discussion</h3><div>Taxane-based adjuvant chemotherapy offers significant survival benefits in older patients with BC, similar to younger patients, yet with increased toxicity.</div></div>","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"16 2","pages":"Article 102184"},"PeriodicalIF":3.0,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142950045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Geriatric Assessment-driven INterventions among Hospitalized older adults with cancer (GAIN-HOSP), a prospective pilot study","authors":"Leana Cabrera Chien,&nbsp;Can-Lan Sun,&nbsp;Heeyoung Kim,&nbsp;Carolina Uranga,&nbsp;Enrique Soto-Perez-de-Celis,&nbsp;Peggy Burhenn,&nbsp;Kemeberly Charles,&nbsp;Jessica Vazquez,&nbsp;Elsa Roberts,&nbsp;Wai Yu (Kim),&nbsp;Jae Y. Kim,&nbsp;Clayton Lau,&nbsp;Stephen Sentovich,&nbsp;Tanya B. Dorff,&nbsp;Mina S. Sedrak,&nbsp;Vani Katheria,&nbsp;Arti Hurria,&nbsp;William Dale,&nbsp;Daneng Li","doi":"10.1016/j.jgo.2024.102063","DOIUrl":"10.1016/j.jgo.2024.102063","url":null,"abstract":"","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"16 1","pages":"Article 102063"},"PeriodicalIF":3.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142289103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The care of older patients with cancer across the United Kingdom in 2024: A narrative review by the International Society of Geriatric Oncology UK Country Group","authors":"Fabio Gomes ,&nbsp;Naomi Farrington ,&nbsp;Jessica Pearce ,&nbsp;Daniel Swinson ,&nbsp;Jenny Welford ,&nbsp;Alastair Greystoke ,&nbsp;Mark Baxter ,&nbsp;Alana G. Brown-Kerr ,&nbsp;Lynda Wyld ,&nbsp;Jenna Morgan ,&nbsp;Nicolò Matteo Luca Battisti ,&nbsp;Anne Barrell ,&nbsp;David Cobben ,&nbsp;Anthea Cree ,&nbsp;Mark Johnston ,&nbsp;Kirsty Colquhoun ,&nbsp;Iain Phillips ,&nbsp;Jemima Smith ,&nbsp;Simon Stapley ,&nbsp;Lisa Lyons ,&nbsp;Kwok-Leung Cheung","doi":"10.1016/j.jgo.2024.102133","DOIUrl":"10.1016/j.jgo.2024.102133","url":null,"abstract":"<div><div>The worldwide population is ageing, alongside an increase in cancer incidence rates. Over the past 10 years, there has been huge progress in the field of oncology with earlier diagnosis and an expansion of treatment options, leading to a growing number of older people living with cancer. That has meant that caring for older patients with cancer is now part of day-to-day oncology practices. This cohort often has geriatric syndromes and a higher prevalence of frailty and complex needs and preparing our clinical services to optimise care for these patients is essential. Whilst it is widely accepted that comprehensive geriatric assessments are of benefit to patients, only a small proportion of patients can access these through specialised teams during their cancer care. In the past few years there has been significant progress in this field throughout the United Kingdom (UK). The goal of this review is to inform other health care systems how to learn from what has been done in the UK. This paper provides an update from our previous review in 2020, detailing the new services being implemented and made available to patients and an expansion in the number of new pilot teams and research projects/trials throughout the four nations of the UK.</div></div>","PeriodicalId":15943,"journal":{"name":"Journal of geriatric oncology","volume":"16 1","pages":"Article 102133"},"PeriodicalIF":3.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142501988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}